Brief: Olema Oncology Advances Op-1250 Into Phase 2 Monotherapy Expansion In Patients With Er+/Her2- Advanced Breast Cancer
09/08/2022 23:13
Aug 9 (Reuters) - Olema Pharmaceuticals Inc OLMA.O :
* OLEMA ONCOLOGY ADVANCES OP-1250 INTO PHASE 2 MONOTHERAPY
EXPANSION IN PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER
Source text for Eikon: ID:nGNX6sh9ZP
Further company coverage: OLMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Olema Oncology
See all newsBrief: Olema Pharmaceuticals Changes Corporate Name To Olema Oncology, Effective Today
Olema Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings Summary
Olema Pharma Q3 net loss widens on higher costs
Brief: Olema Pharmaceuticals Q3 Net Income USD -73.599 Million
Olema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary